2019
DOI: 10.1128/cmr.00031-19
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

Abstract: SUMMARYIn recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant or extensively drug-resistant (MDR/XDR)Pseudomonas aeruginosahas become a public health threat. This article reviews their mechanisms of resistance, epidemiology, and clinical impact and current and upcoming therapeutic options.In vitroandin vivotreatment studies and pharmacokinetic and pharmacodynamic (PK/PD) models are discussed. Polymyxins are reviewed as an important therapeutic option, outlining dosage, p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

8
486
1
12

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 641 publications
(507 citation statements)
references
References 360 publications
(532 reference statements)
8
486
1
12
Order By: Relevance
“…(26,28) Apart from areas with a high prevalence of MBL in P. aeruginosa, the presence of Class A ESBL b-lactamases can result in resistance to ceftolozanetazobactam. (14) Avibactam is an e cient inhibitor of Class A b-lactamases and hence ceftazidime-avibactam combination retains its activity in this situation but not ceftolozane-tazobactam. (29,30) In a report from Spain of 24 extremely-drug resistant ST235 P. aeruginosa isolates, 13% were susceptible to ceftolozane-tazobactam and 58% to ceftazidime-avibactam and the predominant b-lactamases identi ed were VIM-2 (42%) and the Class A ESBL GES-5 (46%).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…(26,28) Apart from areas with a high prevalence of MBL in P. aeruginosa, the presence of Class A ESBL b-lactamases can result in resistance to ceftolozanetazobactam. (14) Avibactam is an e cient inhibitor of Class A b-lactamases and hence ceftazidime-avibactam combination retains its activity in this situation but not ceftolozane-tazobactam. (29,30) In a report from Spain of 24 extremely-drug resistant ST235 P. aeruginosa isolates, 13% were susceptible to ceftolozane-tazobactam and 58% to ceftazidime-avibactam and the predominant b-lactamases identi ed were VIM-2 (42%) and the Class A ESBL GES-5 (46%).…”
Section: Discussionmentioning
confidence: 99%
“…(13) Multiple resistance mechanisms are frequently present in concert resulting in simultaneous resistance to multiple agents. (14) In many settings, P. aeruginosa resistance to b-lactam antibiotics is increasing at alarming rates. In particular, the increasing prevalence of horizontallyacquired b-lactamase genes is especially concerning.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Increasing rates of antibiotic resistance among Gram-negative pathogens such as Pseudomonas aeruginosa represent a serious risk to worldwide health (1,2). The prevalence of multi-drug-resistant (MDR) strains capable to inactivating a broad array of antibiotics has stimulated the development of alternative therapies (3)(4)(5).…”
Section: Introductionmentioning
confidence: 99%
“…It is also known that the P. aeruginosa infections can be critical, with high mortality in cases of ventilator-associated pneumonia [2] or bacteremia [7,8]. effective for treating P. aeruginosa infections, has become a serious problem [9,10]. This resistance in P. aeruginosa is attributed to a variety of mechanisms, including the production of antibiotic-inactivating enzymes such as cephalosporinases, the constitutive expression of various e ux pumps, and the low permeability of the outer membrane [11].…”
Section: Introductionmentioning
confidence: 99%